# Health X Platform share price today (Health X Platform Ltd, NSE: HEALTHX)

> Health X Platform share price today: ₹273.00 at the NSE close on 30 October 2026. Health X Platform (NSE: HEALTHX) trades at a P/E of 37.4. > Health X Platform Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. HEALTHX · Pharmacy Distribution · data as of 30 October 2026. Page: https://www.sectoralpha.in/stocks/health-x-platform-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹273.00
- P/E: 37.4× (higher than 90% of the last 2 years)
- Revenue (Jun 2026): ₹447 Cr (+49.7% on a year ago)
- Profit (Jun 2026): ₹2.0 Cr (−92.5% on a year ago)
- Operating margin: −1.9% (−3.9 points on a year ago)
- ROCE: 0%, FY26

Biggest thing to watch: the P/E is higher than 90% of its own history, so the multiple has already done part of the work. ## What is the Health X Platform share price today? Health X Platform Ltd's share price was ₹273.00 at the close on 30 October 2026. It has been falling for 3 weeks. That is 7.5% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 11 weeks running. Since its first close in our records, on 10 April 2026, it has traded between ₹262 and ₹328, and at that close it sat 17% of the way up from that low. Over the last 7 months the share price moved +1% while the NIFTY 500 moved −3%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 21 August 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Health X Platform this quarter? 9 points on a year earlier. 1. Revenue up on a year earlier for 5 quarters in a row In the June 2026 quarter revenue was ₹447 crore, +49.7% on a year earlier. Why: Revenue rose because Retailer Shakti, the main business, grew 48% and led the platform's growth. Next results: check whether Retailer AI launches and lifts the average share of each pharmacy's spending, which was around 2%. From the earnings call on 11 Aug 2026. 2. Highest quarterly revenue in 15 quarters Revenue of ₹447 crore in the June 2026 quarter is the highest of the last 15 quarters. Why: Revenue hit a record because Retailer Shakti, the main business, grew 48% and led the platform's growth. Next results: check whether capacity additions support up to Rs 3,000 crore of revenue. From the earnings call on 11 Aug 2026. 3. Operating margin down 3.9 points on a year earlier -1.9% in the June 2026 quarter, from 2%. Why: Operating margin fell because SastaSundar's loss was mostly from building technology. Next results: check whether EBITDA, a rough measure of operating profit, is still expected to stay negative for the next 2 to 3 years. From the earnings call on 11 Aug 2026. ## What are Health X Platform's latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Health X Platform reported revenue of ₹447 crore, up 49.7% from ₹298 crore a year earlier, and a profit of ₹1.99 crore, down 92.5% from ₹26.6 crore. ### Health X Platform results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹447 crore | ₹298 crore | +49.7% |
| Profit | ₹1.99 crore | ₹26.6 crore | −92.5% |
| Earnings per share | ₹0.80 | ₹7.52 | −89.4% |
| Operating margin | −1.9% | 2.0% | −3.9 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Health X Platform's management discussed these results on a call held on 11 August 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Health X Platform share price history? Health X Platform closed at ₹273.00 on 30 October 2026. Its highest weekly close since April 2026 was ₹328.25 on 25 June 2026. ### Health X Platform share price: then and now

| When | Close | Change to 30 Oct 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹261.90 | +4.2% |
| 1 month ago · 1 Oct 2026 | ₹273.80 | −0.3% |
| 6 months ago · 30 Apr 2026 | ₹281.75 | −3.1% |
| Earliest weekly close in our records · 10 Apr 2026 | ₹269.20 | +1.4% |
| Highest weekly close since April 2026 · 25 Jun 2026 | ₹328.25 | −16.8% |
| Lowest weekly close since April 2026 · 23 Oct 2026 | ₹261.90 | +4.2% |

Weekly closing prices. Each change is the move from that price to the 30 Oct 2026 close. A day's intraday high or low can go beyond these weekly closes. (37 weekly closes from 10 April 2026 to 30 October 2026.)

## What is the latest news on Health X Platform? 30 Oct 2026: Health X Platform closed at ₹273.00, up 4.2% on the week and down 0.3% on the month. 11 Aug 2026: Health X Platform held its results call for April to June 2026. Management guided: Retailer Shakti positive operating profit in October to December 2026. ### Earlier

- Results for April to June 2026: Revenue up 49.7% and profit down 92.5% on a year earlier. ## What dividend does Health X Platform pay? Health X Platform has paid no dividend on the NSE since its first NSE close in our records (10 April 2026), the start of the period we checked. No. Health X Platform Ltd paid out 0% of its profit as dividends in each of its last 13 reported years, so there is no payout history to show. That comes from the filed annual statements, not an estimate. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Health X Platform management say on the latest results call? On the call for April to June 2026, held on 11 August 2026, Health X Platform's management guided: Retailer Shakti positive operating profit in October to December 2026. > “However, we will extend the so-called burn. We will continue to burn and continue to invest in technology because we are at the infancy stage and have not reached our full potential.”
> BL Mittal, on the call for April to June 2026

### What management guided

- Consolidated operating profit not expected to be positive for the next 2-3 years; technology spending to continue. - Overall FY27 gross margin above 8%. - Gross margin to reach around 12% at scale. - Retailer AI SaaS launch this quarter; success confirmation next quarter, inventory reduction to 5-6 days and wallet share doubling planned. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijorifinance.com/insight/india/5672/Conference Call/CC-Aug26.pdf). (From the call for April to June 2026, 11 August 2026.)

## What to watch in Health X Platform's next results? When Health X Platform reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: RetailerShakti operating leverage and Retailer AI launch - check positive operating profit progress, automation adoption and wallet-share response. - What to check (from the call)
- RetailerShakti operating leverage and Retailer AI launch - check positive operating profit progress, automation adoption and wallet-share response. - Consolidated margin progression - check whether operating leverage offsets continued technology, branding and geographic-expansion spend. - Jito rollout - check HealthBuddy conversion, private-label contribution and pure-play franchise traction. - Fulfillment rollout - check Patna and Lucknow construction, utilisation and capacity additions against the stated geographic plan. ## Which stock lists is Health X Platform on? Health X Platform is on one of our India lists: Pharma stocks. [Pharma stocks Market value (₹ crore): 913.0466321243524](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Health X Platform profitable? Health X Platform Ltd earned ₹2.0 Cr of net profit in the Jun 2026 quarter, −92.5% on the same quarter a year earlier. The full FY26 year was a loss of ₹1.0 Cr. That is 0.4% of the quarter's revenue. The same quarter a year earlier earned ₹26.6 Cr. 6 of the last 12 reported quarters were loss-making. ## How much revenue does Health X Platform make, and is it growing? Health X Platform Ltd reported ₹447 Cr of revenue in the Jun 2026 quarter, +49.7% on the same quarter a year earlier. That is the 5th quarter in a row with growth on the year before. Over 10 years it has grown 31.5% a year on average. The last full year, FY26, came in at ₹1,375 Cr. The last four reported quarters add to ₹1,468 Cr. FY26 revenue was ₹1,375 Cr, +18.6% on the year before. Recent pace: the last four quarters grew +28.4% on average, against 31.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +28.8%, against +5.8% a year over the last 8 quarters (accelerating). ## How much of every ₹100 of sales does Health X Platform keep? Health X Platform Ltd's operating margin was −1.9% in the Jun 2026 quarter, 3.9 percentage points lower than the same quarter a year ago. Across 13 years it has been between −31.0% and 62.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −3.9 percentage points on the year while gross margin changed −4.6 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is Health X Platform's profit turning into cash? Over the last 2 years Health X Platform Ltd's operations used more cash than they brought in, so cash conversion was −20%, a gap worth watching. In FY26 its operations used ₹74.0 Cr of cash, against −₹1.0 Cr of profit. After ₹13.0 Cr of spending on assets, free cash was −₹87.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why −20% of profit came in as cash: the cash cycle got 18 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: no single use of cash stands out. The next section checks both the cash tied up in daily operations and the spending on assets. ## Where does Health X Platform's cash go? Health X Platform Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 20 days in FY26, down from 38 days in FY21. It spent ₹32.0 Cr on assets over the last 3 years. Customers take 2 days to pay, and stock sits for 44 days on average. At FY26 sales of ₹1,375 Cr, each day of that cycle ties up about ₹3.8 Cr, so roughly ₹75.0 Cr is tied up in the business at any time. FY26: customers took 2 days to pay and stock sat for 44 days, about 1.4 months of sales sitting as stock, for a full cycle of 20 days, shorter than FY21's 38. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 44 days. Customers pay about 2 days after that. Suppliers are paid at 26 days. Together that makes the 20-day cycle. Spending on assets: ₹32.0 Cr over the last 3 years, against ₹22.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building a little beyond replacing what wears out. Work still in progress is ₹1.0 Cr (FY26): assets paid for that are not earning yet. In short: neither the daily cycle nor new spending is soaking up the cash, so the picture is fairly clean. ## What is Health X Platform's P/E ratio, and how does it compare with its own history? Health X Platform Ltd's P/E is 37.4×, near the high end of its own history: higher than 90% of past readings. Its usual P/E (the middle reading) is 25.2×, over 2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 388% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Health X Platform business getting better or worse? Health X Platform Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 8 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Health X Platform earn on its capital? Health X Platform Ltd earned a ROCE of 0% in FY26. That is up from a low of −25% in FY20. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −0.1% net margin and 1.48× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −0.1% net margin × 1.48× asset turnover × 1.45× leverage (assets divided by equity) ≈ −0.2% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 388% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Health X Platform have too much debt? Health X Platform Ltd had ₹26.0 Cr of borrowings against ₹641 Cr of equity in FY26, so its debt is 0.04× its equity. Its operating profit is 4 times its interest bill. Over 5 years borrowings went from ₹12.0 Cr to ₹26.0 Cr. Over the last 3 of those years it spent ₹32.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 388% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Health X Platform shareholding pattern? Foreign institutions raised their stake in Health X Platform Ltd by 1.3 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.3% of the company. Domestic institutions moved +0.6 points over the same period, to 2.6%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +1.3 points over 8 quarters, to 2.3%; Domestic institutions: +0.6 points over 8 quarters, to 2.6%; Promoters: +0.1 points over 8 quarters, to 74.1%. Why the owners changed: foreign institutions drove it (+1.3 points), together with domestic institutions (+0.6 points). They raised their stake step by step. ## How far is Health X Platform from balance-sheet trouble? For Health X Platform Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Health X Platform rank in its industry? 45.4 out of 100, rank 3 of 5 in Pharmacy Distribution, with 53% of the evidence available. Health X Platform Ltd scores 45.4 out of 100 against the 5 companies it is compared with in Pharmacy Distribution, ranking 3. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 18.5 + 8.6 + 10 + 8.3 = 45.4. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Health X Platform compared with? Health X Platform ranks 3 of 5 Pharmacy Distribution companies on the 4-Factor Sector Score, with 45.4 out of 100. 1. [Entero Healthcare Solutions Ltd](https://www.sectoralpha.in/stocks/entero-healthcare-solutions-ltd) ENTERO · breaking out · Most evidence points up · 68% evidence 68.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.8/35 · Revenue 31.9% · Profit 44.8% · Operating margin change 1.4 points · 83% evidence Capital efficiency 14.1/25 · ROCE 10.5% · Operating margin 5% · 76% evidence Valuation 10.0/20 · P/E 53.2× · PEG n/a · 0% evidence Relative strength 20.0/20 · Lead over its industry 27% · Lead over NIFTY 500 30.4% · 1 year 42.5% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.8 + 14.1 + 10 + 20 = 68.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Zota Health Care Ltd](https://www.sectoralpha.in/stocks/zota-health-care-ltd) ZOTA · turning · Too little evidence to rank firmly · 56% evidence 45.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.6/35 · Revenue 68.9% · Profit -80% · Operating margin change -3.4 points · 74% evidence Capital efficiency 1.3/25 · ROCE -8.5% · Operating margin 1.5% · 100% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 12.5/20 · Lead over its industry n/a · Lead over NIFTY 500 6.3% · 1 year -12.1% · 25% evidence · 3 of 12 weeks ahead Exact sum: 21.6 + 1.3 + 10 + 12.5 = 45.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. Health X Platform Ltd this page HEALTHX · quiet · Too little evidence to rank firmly · 53% evidence 45.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 18.5/35 · Revenue 28.9% · Profit 82.5% · Operating margin change -3.9 points · 83% evidence Capital efficiency 8.6/25 · ROCE 0% · Operating margin -1.9% · 76% evidence Valuation 10.0/20 · P/E n/a · PEG n/a · 0% evidence Relative strength 8.3/20 · Lead over its industry n/a · Lead over NIFTY 500 -3.4% · 1 year n/a · 25% evidence · 1 of 12 weeks ahead Exact sum: 18.5 + 8.6 + 10 + 8.3 = 45.4 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 4. [Medplus Health Services Ltd](https://www.sectoralpha.in/stocks/medplus-health-services-ltd) MEDPLUS · basing · Evidence leans down · 90% evidence 44.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.2/35 · Revenue 20.6% · Profit 8.2% · Operating margin change -1 points · 100% evidence Capital efficiency 18.1/25 · ROCE 12.6% · Operating margin 8% · 100% evidence Valuation 13.5/20 · P/E 33× · PEG 1 · 50% evidence Relative strength 0.0/20 · Lead over its industry -25% · Lead over NIFTY 500 -22.7% · 1 year -24% · 100% evidence · 0 of 12 weeks ahead Exact sum: 13.2 + 18.1 + 13.5 + 0 = 44.8 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far. 5. [Sastasundar Ventures Ltd](https://www.sectoralpha.in/stocks/sastasundar-ventures-ltd) SASTASUNDR · Too little evidence to rank firmly · 36% evidence 39.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.1/43.75 · Revenue 8.8% · Profit 100% · Operating margin change 5.4 points · 33% evidence Capital efficiency 6.8/31.25 · ROCE -1.3% · Operating margin -3% · 71% evidence Valuation 9.3/25 · P/E 33.7× · PEG n/a · 35% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 23.1 + 6.8 + 9.3 = 39.2 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharmacy Distribution](https://www.sectoralpha.in/sectors/pharmacy-distribution), all 5 compared on one page. ## Which companies are close to Health X Platform in size? Health X Platform is the 4th largest of 5 Pharmacy Distribution companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Medplus Health Services, Entero Healthcare Solutions and Zota Health Care. Just below it: Sastasundar Ventures. ### Pharmacy Distribution companies close in size

1. [Medplus Health Services Ltd](https://www.sectoralpha.in/stocks/medplus-health-services-ltd) ₹6,968 crore
2. [Entero Healthcare Solutions Ltd](https://www.sectoralpha.in/stocks/entero-healthcare-solutions-ltd) ₹6,863 crore
3. [Zota Health Care Ltd](https://www.sectoralpha.in/stocks/zota-health-care-ltd) ₹4,602 crore
4. Health X Platform Ltd ₹921 crore
5. [Sastasundar Ventures Ltd](https://www.sectoralpha.in/stocks/sastasundar-ventures-ltd) ₹874 crore

[All 5 Pharmacy Distribution companies, largest first](https://www.sectoralpha.in/sectors/pharmacy-distribution#all-companies)

### Companies close in size in other industries

1. [Commercial Syn Bags Ltd](https://www.sectoralpha.in/stocks/commercial-syn-bags-ltd) ₹852 crore · Packaging - Polysacks
2. [Shree Vasu Logistics Ltd](https://www.sectoralpha.in/stocks/shree-vasu-logistics-ltd) ₹850 crore · Miscellaneous
3. Health X Platform Ltd ₹849 crore
4. [SJ Corporation Ltd](https://www.sectoralpha.in/stocks/sj-corporation-ltd) ₹845 crore · Diamond, Gems & Jewellery
5. [RSWM Ltd](https://www.sectoralpha.in/stocks/rswm-ltd) ₹843 crore · Textiles - Spinning

## What else do people ask about Health X Platform? ### What is Health X Platform's share price today? Health X Platform Ltd's share price is ₹273.00. The whole company is worth ₹921 Cr on the market. In the last 52 weeks it traded between ₹262 to ₹328; today it is 17% of the way up from the low, 7.5% below its 200-day average. The price has been falling for 3 weeks (as of 30 October 2026). ### What were Health X Platform's latest quarterly results? Health X Platform Ltd reported revenue of ₹447 Cr and net profit of ₹2.0 Cr for the Jun 2026 quarter. Revenue rose 49.7% and profit fell 92.5% compared with a year earlier. Earnings per share were ₹0.80. The operating margin was −1.9%, 3.9 percentage points lower than a year earlier (as of 30 October 2026). ### What is Health X Platform's market cap? Health X Platform Ltd's market capitalisation is ₹921 Cr at a share price of ₹273.00. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 30 October 2026). ### How is Health X Platform performing? Health X Platform Ltd's share price has been falling for 3 weeks. In its latest quarter, revenue rose 49.7% and profit fell 92.5% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 11 weeks running (as of 30 October 2026). ### Is Health X Platform in an uptrend? No, the price has been falling for 3 weeks (stage 4 of 4), 7.5% below its 200-day average, and 17% of the way up its 52-week range. A share price tends to move through four phases: moving sideways, rising, stalling and falling (as of 30 October 2026). ### Will Health X Platform's share price go up? This page does not forecast Health X Platform Ltd's share price. What it shows instead: the share price is ₹273.00, and it has been falling for 3 weeks. Its P/E of 37.4× is higher than 90% of its own last 2 years (as of 30 October 2026). ### Who owns Health X Platform? Promoters own 74.1% of Health X Platform Ltd, foreign institutions 2.3%, domestic institutions 2.6% and the public 21.0% (latest quarter). The biggest change over the last two years: Foreign institutions raised their stake by 1.3 percentage points over 8 quarters (as of 30 October 2026). ### Where is Health X Platform in its business cycle? Health X Platform Ltd's FY26 operating margin was 0.3%, against a 13-year range of −31.0% to 62.0%: the middle of its own range, neither a peak nor a low. The latest quarter was −1.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 30 October 2026). ### What could break the Health X Platform story? Biggest thing to watch: the P/E is higher than 90% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 30 October 2026). ### Is Health X Platform a stock worth studying right now? What the numbers show: Health X Platform Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 30 October 2026). ### Is there a Health X Platform share price forecast for 2026? What management itself guided: Retailer Shakti positive operating profit in October to December 2026. ## Lists

- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.